4.245

0.70% 0.025

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $4.245, with a volume of 603.62K. It is up +0.70% in the last 24 hours and up +11.24% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$4.22

Open:

$4.2

24h Volume:

603.62K

Relative Volume:

0.84

Market Cap:

$420.88M

Revenue:

$9.01M

Net Income/Loss:

$-99.72M

P/E Ratio:

-0.9354

EPS:

-4.5381

Net Cash Flow:

$-92.85M

1W Performance:

-0.01%

1M Performance:

+11.24%

6M Performance:

+37.08%

1Y Performance:

+49.11%

1-Day Range:

$4.13

$4.335

1-Week Range:

$4.05

$4.55

52-Week Range:

$2.45

$4.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

Twitter

@x4pharma

Next Earnings Date

2026-08-14

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	4.245	418.40M	9.01M	-99.72M	-92.85M	-4.5381
VRTX Vertex Pharmaceuticals Inc	515.27	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.54	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.75	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.57	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.12	39.31B	5.76B	514.49M	1.10B	4.4813

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	Guggenheim	Buy
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

06:31 AM

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com

06:31 AM

Aug 14, 2026

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan

Aug 14, 2026

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView

Aug 14, 2026

4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool

Aug 14, 2026

Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan

Aug 14, 2026

Aug 13, 2026

X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media

Aug 13, 2026

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat

Aug 13, 2026

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat

Aug 13, 2026

X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com

Aug 13, 2026

X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India

Aug 13, 2026

X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media

Aug 13, 2026

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan

Aug 13, 2026